QUICKLINKS AND VIEW OPITONS
People who used beta blockers in a Hypertension Clinic weighed 37.9 lbs more than Non-Users
Saturday, July 14, 2018 6:20 am Email this article
Among a total of 84 consecutive patients attending a hypertension clinic, 50% were taking beta blockers to lower blood pressure according to a study from Australia.
Those taking beta blockers were 37.9 pounds heavier than patients not taking a beta blocker (197 lbs vs 159 lbs).
Beta blockers are drugs are given for:
- abnormal heart rhythms
- High blood pressure
- Heart failure
- Angina (heart pain)
- Prevention of migraines
- given after a heart attack
- akathisia (restlessness or inability to sit still)
- panic disorder
- aggressive behavior
Diet-induced thermogenesis reduced 50% in beta blocker users compared to controls
The researchers found that beta blockers reduced diet-induced thermogenesis 50% compared to controls.
Fat oxidation reduced 32% in beta blocker users compared to controls
The researchers found that beta blockers reduced fat oxidation by 32% compared to controls.
Weekly habitual activity reduced 30% in beta blocker users compared to controls
The researchers found that beta blockers reduced weekly habitual activity by 30% compared to controls.
Beta blockers can cause weight gain and obesity because they decrease calories burned
The researchers concluded that beta blockers reduce energy expenditure (EE), and increase body weight and can cause obesity because of the decrease in energy expenditure.
Duration of Beta-blocker Use
Duration of Beta-blocker use: Average of 12 years
Everyone using Beta-blockers had taken them for at least 3 years, and the average length of time for having taken them was 12 years.
Subjects: 42 Beta-blocker users vs 42 non-users
The study involved 42 Beta-blocker users versus 42 non-users.
Obese patients were NOT more likely to be given a Beta-blocker
They did NOT find that obese patients were more likely to be prescribed a Beta-blocker
“It is possible that the association between Beta-blocker use and greater weight is confounded by a greater prescriptive use of anti-hypertensive agents to patients who are more obese. However, we did not find evidence for this among patients from the hypertension clinic.” the paper notes.
“In addition, analysis revealed that differences in anthropo- metric measures attributable to Beta-blocker use remained significant after adjusting for the concurrent use of other anti-hypertensive medications,” they continued.
“The observation that BMI among Beta-blocker users with diabetes was not different between those receiving polytherapy [multiple drugs] and monotherapy [Beta-blocker as the only blood pressure drug], suggests polytherapy itself was not associated with higher BMI.
Beta-blocker Use Associated with Obesity
‘Strong evidence’ that Beta-blocker increase the risk of obesity
“These findings support an independent association of Beta-blocker with obesity,” the paper states.
“The striking consistency in weight difference observed between Beta-blocker treated and non-treated patients in three different settings provide strong evidence for an obesogenic effect of Beta-blocker therapy, as supported by mechanistic evidence from evaluation of [ energy expenditure ].”
Lee P, Kengne A, Greenfield J, Day R, Chalmers J, Ho K. Metabolic sequelae of beta-blocker therapy: Weighing in on the obesity epidemic? Int J Obes (Lond). 2011 Feb 8, advanced on-line publication.
AUTHOR’S CONTACT INFORMATION
Professor KKY Ho
Pituitary Research Unit
Garvan Insitute of Medical Research
384, Victoria Street
Darlinghurst, Sydney, New South Wales, Australia
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.